← Markets

Iovance Biotherapeutics, Inc.

IOVA · NASDAQ

Market closed$5.00$0.340000 (+7.30%)After hours $5.02 · +0.40%

Key statistics

Previous close$4.66
Open$4.54
Day high$5.06
Day low$4.44
52-week high$5.63
52-week low$1.76
Market cap1.79B
Volume23.12M
Average volume15.18M
P/E ratio-5.26
Forward P/E—
EPS-0.95
Dividend yield0.00%

Market context

Why it moved

Iovance Biotherapeutics shares surged following positive market momentum and investor optimism around the company's ongoing commercial rollout of its TIL therapy AMTAGVI, with the stock continuing its recovery from recent lows amid increased trading volume.

StockinvestTradingviewApartmentsIowapublicradioMarketbeat

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Iovance Biotherapeutics surged on above-average volume, with shares closing up 7.3%, as investors appeared to respond to the company's reiterated 2026 full-year revenue guidance of $350–$370M and advancing pipeline momentum — including FDA IND clearance for its next-gen IL-12 TIL therapy and recent Australian approval for Amtagvi. The move builds on a broader reassessment of the beaten-down biotech, which carries a consensus 'Strong Buy' rating and average analyst price target of $9, implying significant upside from current levels.

7.2961

July 16, 2026Iovance Biotherapeutics surged over 20% on volume nearly three times its daily average, as investors appeared to reassess the stock in what analysts describe as a catch-up rally and short-covering move tied to the company's reiterated 2026 revenue guidance of $350M–$370M and strengthening pipeline momentum. The move was supported by an early July 8-K filing updating Iovance's corporate presentation, FDA clearance of the IND for next-gen IL-12 TIL therapy IOV-5001 with a Phase 1/2 trial set to begin in H2 2026, and Australian approval of Amtagvi for advanced melanoma — all reinforcing improving commercial and regulatory execution. The healthcare sector held broadly steady, and UBS separately upgraded healthcare as a key allocation focus, citing improving earnings revisions and a biotechnology M&A rebound as a favorable backdrop for names like Iovance.

20.6107

July 15, 2026Iovance Biotherapeutics closed down nearly 3% as the broader healthcare sector faced headwinds, with the XLV ETF also finishing lower amid a difficult day for healthcare names including Abbott and UnitedHealth. The decline comes as investors weigh the company's ongoing Amtagvi commercial ramp — guided at $350M–$370M in 2026 revenue — against sector-wide earnings concerns and a biotech sub-sector facing a projected 79% Q2 earnings drop. Despite strong long-term analyst conviction (consensus 'Strong Buy', average price target ~$9), IOVA has pulled back roughly 5% over the past month.

-2.7228

July 14, 2026Iovance Biotherapeutics declined alongside a broader market selloff driven by renewed U.S.-Iran military tensions that sent oil prices surging and dampened risk appetite, particularly for smaller biotech names. Despite the macro headwinds, the company's fundamental narrative remains constructive — Amtagvi continues its commercial ramp with analyst consensus implying significant upside, and Goldman Sachs recently highlighted biotech as a sector poised to extend its rally amid rising M&A activity and strong innovation cycles.

-4.4917

July 11, 2026Iovance Biotherapeutics closed down roughly 3% as investors weighed a recent corporate presentation refresh spotlighting its tumor infiltrating lymphocyte (TIL) therapy platform and over 1,500 patients treated, alongside a Simply Wall St. analysis suggesting shares may be 76% undervalued. The pullback comes despite a broadly constructive biotech backdrop — Jim Cramer recently dubbed biotech the market's hottest group and the XLV healthcare ETF has pushed to record highs — with the stock's narrative remaining centered on Amtagvi's sales ramp toward full-year guidance of $350–$370M and margin expansion, while international approval setbacks in the U.K. and Europe continue to weigh on sentiment.

-3.2037

July 10, 2026Iovance Biotherapeutics shares rose roughly 2%, buoyed by a broader biotech sector rally as Jim Cramer declared biotech 'the hottest group in the market' and predicted a wave of M&A deals under a more favorable FDA backdrop. The healthcare sector outperformed the broader market, with XLV posting strong recent gains, providing a tailwind for speculative biotech names like Iovance. Investor attention remains focused on the company's Amtagvi commercial trajectory — Q2 is guided to be a record quarter — and pending regulatory resubmissions in the U.K. and Europe after earlier setbacks, while analysts maintain an average price target near $9, implying significant upside from current levels.

2.1028

July 9, 2026Iovance Biotherapeutics shares declined modestly, closing down about 1.6%, as a broad market risk-off move driven by renewed U.S.-Iran tensions and surging oil prices weighed on equities broadly. Despite the session's pullback, the stock is trading slightly higher in after-hours. The broader backdrop remains constructive for the company: biotech has been the market's hottest rotation trade, with Jim Cramer and analysts flagging the sector as a prime M&A target amid a friendlier FDA environment. For Iovance specifically, investors continue to monitor Amtagvi's commercial ramp—the company guides for $350–370M in 2026 revenue—while pending resubmissions to U.K. and European regulators remain key milestones.

-1.6092

July 8, 2026Iovance Biotherapeutics rose nearly 4%, outperforming a broadly softer market, as healthcare continued its recent winning streak and biotech sentiment surged on Jim Cramer's call that biotech is "the hottest group in the market," predicting a wave of M&A deals under the more favorable FDA regulatory environment. Iovance, with its first-in-class FDA-approved TIL therapy Amtagvi and guidance for $350–$370M in 2026 revenue, fits the profile of an acquisition candidate analysts have highlighted, while a broader rotation into healthcare — XLV near its 52-week high — provided additional tailwinds.

3.8186

Seeking Alpha · July 17, 2026Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy) (NASDAQ:IOVA)Quiver Quantitative · July 15, 2026IOVA stock jumps as investors appear to focus on reiterated 2026 guidance and pipeline progressInvesting.com · May 20, 2026Iovance Biotherapeutics’ SWOT analysis: stock gains momentum on melanoma dataStocktwits · February 24, 2026Why Did IOVA Stock Gain Pre-Market Today?
Mt Newswire · June 18, 2026Iovance Biotherapeutics Files Mixed Shelf
Benzinga · June 18, 2026Iovance Biotherapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
Mt Newswire · June 3, 2026Iovance Biotherapeutics Wins Conditional Australian Approval for Amtagvi in Advanced Melanoma
Benzinga · June 3, 2026Iovance Biotherapeutics Says Therapeutic Goods Administration Of Australia Grants Approval With Conditions Of Amtagvi, Tumor-Derived Autologous T Cell Immunotherapy, For Previously Treated Advanced Melanoma
Mt Newswire · June 1, 2026Iovance Biotherapeutics Receives US FDA Clearance to Begin IOV-5001 Trial in Solid Tumors
Benzinga · June 1, 2026Iovance Biotherapeutics Announces Allowance To Proceed From FDA For Investigational New Drug Application For Phase 1/2 Basket Study Of IOV-5001
Benzinga · May 8, 2026Chardan Capital Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $14
Mt Newswire · May 7, 2026Iovance Biotherapeutics Shares Drop After Q1 Results Miss

Peers

S&P 500SPX · $7,457.69-1.01%Lantheus Holdings, Inc.LNTH · $107.59+2.36%PTC Therapeutics, Inc.PTCT · $78.59+0.09%Scholar Rock Holding CorporationSRRK · $52.86+2.18%Xenon Pharmaceuticals Inc.XENE · $68.26+1.91%Syndax Pharmaceuticals, Inc.SNDX · $22.80+0.40%Nurix Therapeutics, Inc.NRIX · $23.12+0.22%uniQure N.V.QURE · $40.25+2.26%ArriVent BioPharma, Inc.AVBP · $33.19+1.31%Geron CorporationGERN · $1.44+1.41%Artiva Biotherapeutics, Inc.ARTV · $9.76+7.96%Nkarta, Inc.NKTX · $2.600.00%